Press Releases & Events
Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3) in a Phase I dose escalation study, evaluating the safety and efficacy of Tessa’s TT11X – Allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy.
Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company’s lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over 10 years as Chief Financial Officer of various publicly listed and privately held entities.
Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from two investigator-sponsored Phase 1/2 trials led by Baylor College of Medicine and the University of North Carolina Lineberger Comprehensive Cancer Center.
Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive Officer, and Göran A. Ando will become Chairman of the Board, with immediate effect.
RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center for the autologous T cell therapy
State-of-the-art manufacturing facility will support clinical and commercial production of cell therapies for thousands of patients annually worldwide.
Tessa Therapeutics has established a new Scientific Advisory Board (SAB) with the appointment of a team of highly respected scientists, practicing clinicians and industry veterans.
Tessa Therapeutics today announced ‘proof-of-concept’ data from the preclinical study of TT16, a first-of-its-kind combination immunotherapy that integrates Chimeric Antigen Receptor (CAR) T cell therapy and oncolytic adenovirus expressing immunomodulatory molecules for the treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-positive solid tumors.
Mr Buchalter brings over thirty years’ experience in the biopharmaceutical industry, with strong corporate leadership and an extensive background in the commercial positioning and development of therapeutics in oncology.
Tessa Therapeutics announced that Dr. George W. Sledge, Jr., M.D., Professor and Chief of Medical Oncology at Stanford University Medical Center, will join Tessa’s Board of Directors as an independent director, effective 2 January 2019.
Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, today announced the appointment of Ivan D. Horak as President of Research and Development. In his new position, Dr. Horak will be responsible for all aspects of Tessa’s research and development, regulatory and clinical development activities.
St. Jude Children’s Research Hospital (St. Jude), the U.S. hospital leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases, together with Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the establishment of a strategic collaboration focusing on the development of novel cellular immunotherapies that could lead to new treatment options for children with brain cancer.
Tessa Therapeutics is delighted to announce that Göran Ando, the former Chairman of Novo Nordisk A/S, has joined the Board as an Independent Director. The company also announces that, due to additional demand in its latest funding round, it has raised a further USD 50m, bringing the total raised in this round to USD 130 million.
With the Stanford Cancer Institute joining as a clinical trial partner, Tessa’s Phase III trial for nose cancer (nasopharyngeal cancer) is now widely accessible across multiple locations in the U.S. The therapy is based on Tessa’s Virus-Specific T cell platform which is showing compelling results in the treatment of solid tumors.
Proceeds to be used to further develop Tessa’s advanced solid tumor immunotherapy pipeline. Funding round reinforces Tessa’s position as an emerging leader in cellular immunotherapy with the vision of bringing transformational change to cancer therapy.
Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for solid tumors, today announces the appointment of Mr. Desmond Lim as Chief Financial Officer.
Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the appointment of Ms. Jennifer Butler as Chief Commercial Officer…
Tessa Therapeutics (Tessa) and the Parker Institute for Cancer Immunotherapy (Parker Institute) today announced the establishment of a multi-year strategic alliance to combine their capabilities to jointly advance research in the field of cancer immunotherapy…
Tessa Therapeutics (Tessa) presented biomarker data from its Phase II trial for its lead candidate TT10, Epstein-Barr virus specific autologous cytotoxic T lymphocyte (CTL) therapy targeting advanced nasopharyngeal carcinoma, at ASCO’s annual meeting, 2017…
Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, and Vyriad, an oncolytic virotherapy company using engineered viruses to destroy tumors and boost the antitumor immune response, today announced a collaboration that will enable Tessa and Vyriad to investigate T cell and oncolytic virus combination therapies…
Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, today announced the full acquisition of Euchloe Bio, a biotechnology company specializing in the development and commercialization of antibodies to treat cancer…
Tessa Therapeutics, an immunotherapy company dedicated to revolutionizing the treatment of cancer, today announced the formation of a joint immuno-oncology laboratory located in A*STAR’s Institute of Molecular and Cell Biology (IMCB)…